Archive for the ‘Anemia’ Category

February 12, 2010

Secondary analysis of the CHOIR trial epoetin-|[alpha]| dose and achieved hemoglobin outcomes

.   .   

This interesting secondary analysis of the CHOIR trial demonstrates that patients achieving their assigned Hb target had better outcomes than those that did not achieve target.  Furthermore, those patients randomized to a higher Hb target, who actually reached that target, saw no increased risk.  This study raises the question whether it is the high dose […]

Comments Off on Secondary analysis of the CHOIR trial epoetin-|[alpha]| dose and achieved hemoglobin outcomes Posted in Anemia, Chronic Kidney Disease
January 11, 2010

Erythropoiesis-Stimulating Agents — Time for a Reevaluation

.   .   

This NEJM “Perspectives” article from the Food and Drug Administration discusses the data driving a need to re-evaluate the use of ESAs in the treatment of anemia due to chronic kidney disease.

Comments Off on Erythropoiesis-Stimulating Agents — Time for a Reevaluation Posted in Anemia, Editorial
January 11, 2010

Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia?

.   .   

This editorial by Dr. Ajay Singh discusses the implications of TREAT in the context of the existing evidence base on the management of anemia due to chronic kidney disease.

Comments Off on Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia? Posted in Anemia, Chronic Kidney Disease, Editorial
October 31, 2009

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

This randomized, double-blind, placebo-controlled trial compared a strategy of initiating darbepoetin alfa at a threshold hemoglobin of 11.0 g per deciliter, with a goal of 13 g per deciliter, versus placebo, with rescue darbepoetin alfa when Hb fell below 9.0 g per deciliter. Patients studied included those with diabetes, CKD (defined as GFR 20-60 ml/min) and anemia. No difference […]

3 Comments Posted in Anemia, Chronic Kidney Disease
October 31, 2009

Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence

This editorial provides insight into the interpretation of the TREAT study, “A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease”.

1 Comment Posted in Anemia, Chronic Kidney Disease
September 13, 2009

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes

While not a peer-reviewed publications, Nephrology Now readers will likely be interested in this preliminary announcements of key findings of the TREAT study which looks at anemia treatment in CKD patients with diabetes.

1 Comment Posted in Anemia, Chronic Kidney Disease
July 10, 2009

The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease

.   .   

This systematic review aims to look at the health-related quality of life (HQOL) impact of target hemoglobin (Hb) levels. Results of this meta-analysis suggest that levels in excess of 120 g/L lead to small, but not meaningful improvements in HQOL. The authors conclude that, in balance with safety concerns, 90 to 120 g/L should be […]

3 Comments Posted in Anemia, Chronic Kidney Disease
May 2, 2009

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

.   .   

This meta-analysis of 53 previous randomized-controlled trials was done to compare erythopoietic agents plus red blood cell transfusions to transfusions alone in the management of anemia in patients with cancer. This study showed that treatment with erythropoiesis-stimulating agents resulted in increased mortality in patients with cancer.

Comments Off on Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Posted in Anemia, Internal Medicine for Nephrologists
August 1, 2008

Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?

.   .   

Comments Off on Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels? Posted in Anemia
August 1, 2008

Canadian Society of Nephrology Clinical Practice Guidelines for the Management of Anemia Associated with Chronic Kidney Disease

.   .   

Comments Off on Canadian Society of Nephrology Clinical Practice Guidelines for the Management of Anemia Associated with Chronic Kidney Disease Posted in Anemia
March 1, 2008

Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo.

.   .   

Comments Off on Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. Posted in Anemia
March 1, 2008

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

.   .   

2 Comments Posted in Anemia
February 1, 2008

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.

.   .   

Comments Off on Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Posted in Anemia